The European Pharma worries following the EU-USA trade agreement

“Customs duties on drugs are a brutal instrument that will disturb the supply chains. Nevertheless, ” fears in particular the European Federation of the Sector (EFPIA). Moreover,

The European. Moreover, French federations of the pharmaceutical industries expressed their concerns on Tuesday regarding the trade agreement between the European Union and the United States. Nevertheless, The latter leaves the drug sector for the moment in uncertainty concerning customs duties.

“Customs duties on drugs are a brutal instrument that will disrupt the supply chains. Consequently, will have an impact on investments in research and development, and, in the end, will harm patient access to drugs on both sides of the Atlantic,” said the European Sector Federation (EFPIA) in a press release. EFPIA “continues to examine the announcements concerning the US-Etats trade agreement, as key implications for the pharmaceutical sector remain uncertain”.

US President european pharma worries following eu-usa Donald Trump. the president of the European Commission Ursula von der Leyen concluded a customs agreement on Sunday, providing that European products exported to the United States be taxed at 15%. Trump warned that pharmaceutical products. so far exempt from a 1994 agreement from the World Trade Organization (WTO), will not benefit from particular treatment, without however giving details.

In early July. he had threatened to impose 200% surcharge on pharmaceutical products imported into the United States if production was not quickly repatriated to American soil. For EFPIA. “there are more effective means that would contribute, rather than hindering, global advances in patient care and economic growth”.

The Federation calls for “rethinking the valuation of innovation” in Europe and increasing investments in innovative drugs. For its part. the professional organization which represents the companies of the drug operating in France (Leem) estimates in a separate press release that “the situation european pharma worries following eu-usa of uncertainty on customs tariffs in the pharmaceutical sector is deeply worrying”.

“Pharmaceutical products must explicitly. permanently be excluded from any tariff measure,” said Leem, recalling that “drugs, vaccines, medical devices and pharmaceutical inputs are not goods like the others”. Imposing customs tariffs on drugs would lead. according to the union, “an increase in production costs, aggravate the difficulties of supply and hinder investment and research and development capacities in Europe”.